The FDA approval of Thermo Fisher’s Oncomine Dx Express Test marks a key advancement in precision oncology, enabling fast, accurate detection of EGFR exon 20 insertion mutations and guiding NSCLC patients to targeted treatments like ZEGFROVY....
Breakthrough polymer platform aims to improve sensitivity, stability, and efficiency across diagnostic assays and lab workflows....
FDA clears assay as companion diagnostic for ZEGFROVY™ and broad tumor profiling, advancing precision oncology diagnostics....
Commercial Launch Marks a Key Step in Enhancing Early Detection of Acute Kidney Injury through Biomarker-Based Testing ...
New technology isolates extracellular vesicles from blood to enable earlier, non-invasive disease detection and personalized treatment strategies....
The partnership aims to deliver a non-invasive, hospital-compatible diagnostic using Aptamer’s Optimer binders and Neuro-Bio’s novel early-stage biomarker, with commercial rollout targeted within 12–18 months....
Unveiled at ESCMID Global Congress 2025, the new Hyperbaric Heating-based platform eliminates the need for extraction kits—delivering faster, simpler, and cost-effective molecular workflows across diverse research and diagnostic applications....
New results from the VERIFI study show Immunovia's test accurately detects 77% of early-stage cases and maintains strong specificity across diverse high-risk groups—strengthening commercial launch plans for Q3 2025....
With low false positives and broad detection capabilities, Volition’s Nu.Q® test could reshape the $20B liquid biopsy market, as the company advances licensing talks with major diagnostic players. ...
Collaboration aims to enhance pharmaceutical innovation and expand access to high-quality healthcare solutions worldwide. ...
